Tokai Pharmaceuticals Company Profile (NASDAQ:NVUS)

About Tokai Pharmaceuticals (NASDAQ:NVUS)

Tokai Pharmaceuticals logoNovus Therapeutics, Inc., formerly Tokai Pharmaceuticals, Inc., is a pharmaceutical company. The Company is focused on the acquisition, development, and commercialization of ear, nose, and throat products. It has two platforms: OP-01 Foam Platform and OP-02 Surfactant Program. OP-01 is developed with the intent to be used as a delivery vehicle for drugs treating ears, as well as the nasal and sinus cavities. OP-01 is currently being developed as an improved treatment option for acute otitis externa. OP-02 is a daily nasal spray that is designed to improve and maintain a healthy middle ear. OP-02 is being developed as a potential treatment option for patients with otitis media and Eustachian tube dysfunction. OP-02 is a combination drug product, which comprises two components: surfactant dipalmitoylphosphatidylcholine and a spreading agent cholesteryl palmitate. The product is sprayed through the nostrils toward the opening of the Eustachian tube at the back of the nasal cavity.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biopharmaceuticals
  • Sub-Industry: N/A
  • Symbol: NASDAQ:NVUS
  • CUSIP: N/A
  • Web: novustherapeutics.com
Capitalization:
  • Market Cap: $2.78 million
  • Outstanding Shares: 740,000
Average Prices:
  • 50 Day Moving Avg: $4.76
  • 200 Day Moving Avg: $6.08
  • 52 Week Range: $3.42 - $18.83
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -9.64
  • P/E Growth: 0.01
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: ($4.06) per share
  • Price / Book: -0.93
Profitability:
  • EBIDTA: ($5,090,000.00)
  • Return on Equity: -138.81%
  • Return on Assets: -121.03%
Debt:
  • Debt-to-Equity Ratio: 0.01%
  • Current Ratio: 7.86%
  • Quick Ratio: 7.86%
Misc:
  • Average Volume: 22,666 shs.
  • Beta: 0.73
  • Short Ratio: 4.22
 

Frequently Asked Questions for Tokai Pharmaceuticals (NASDAQ:NVUS)

What is Tokai Pharmaceuticals' stock symbol?

Tokai Pharmaceuticals trades on the NASDAQ under the ticker symbol "NVUS."

How were Tokai Pharmaceuticals' earnings last quarter?

Tokai Pharmaceuticals, Inc. (NASDAQ:NVUS) posted its earnings results on Tuesday, May, 10th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.50) by $0.01. View Tokai Pharmaceuticals' Earnings History.

Where is Tokai Pharmaceuticals' stock going? Where will Tokai Pharmaceuticals' stock price be in 2017?

1 analysts have issued 12 month price targets for Tokai Pharmaceuticals' stock. Their predictions range from $1.15 to $1.15. On average, they expect Tokai Pharmaceuticals' share price to reach $1.15 in the next twelve months. View Analyst Ratings for Tokai Pharmaceuticals.

Who are some of Tokai Pharmaceuticals' key competitors?

Who are Tokai Pharmaceuticals' key executives?

Tokai Pharmaceuticals' management team includes the folowing people:

  • Keith A. Katkin, Chairman of the Board
  • Gregory J. Flesher, President, Chief Executive Officer, Director
  • Jon Kuwahara, Senior Vice President - Finance and Administration
  • Catherine Turkel, Chief Development Officer
  • Erez Chimovits, Director
  • Cheryl L. Cohen, Director
  • Gary A. Lyons, Director
  • John S. McBride, Director
  • Jodie Pope Morrison, Director

Who owns Tokai Pharmaceuticals stock?

Tokai Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (5.78%) and Lyon Street Capital LLC (5.51%). Company insiders that own Tokai Pharmaceuticals stock include Catherine C Turkel, Gregory J Flesher, John S Mcbride, Lee Kalowski and Stephen Jr Buckley. View Institutional Ownership Trends for Tokai Pharmaceuticals.

Who bought Tokai Pharmaceuticals stock? Who is buying Tokai Pharmaceuticals stock?

Tokai Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc. and Lyon Street Capital LLC. Company insiders that have bought Tokai Pharmaceuticals stock in the last two years include Catherine C Turkel, Gregory J Flesher and Stephen Jr Buckley. View Insider Buying and Selling for Tokai Pharmaceuticals.

How do I buy Tokai Pharmaceuticals stock?

Shares of Tokai Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Tokai Pharmaceuticals' stock price today?

One share of Tokai Pharmaceuticals stock can currently be purchased for approximately $3.76.


MarketBeat Community Rating for Tokai Pharmaceuticals (NASDAQ NVUS)
Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  68 (Vote Outperform)
Underperform Votes:  64 (Vote Underperform)
Total Votes:  132
MarketBeat's community ratings are surveys of what our community members think about Tokai Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Tokai Pharmaceuticals (NASDAQ:NVUS) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $1.15 (69.41% downside)

Analysts' Ratings History for Tokai Pharmaceuticals (NASDAQ:NVUS)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/24/2016BMO Capital MarketsReiterated RatingMarket Perform$1.70 -> $1.15N/AView Rating Details
8/10/2016William BlairReiterated RatingNeutralN/AView Rating Details
7/28/2016Bank of America CorporationDowngradeNeutral -> UnderperformN/AView Rating Details
7/26/2016Stifel NicolausDowngradeBuy -> HoldN/AView Rating Details
7/26/2016Janney Montgomery ScottDowngradeBuy -> NeutralN/AView Rating Details
7/26/2016Wells Fargo & CompanyDowngradeOutperform -> Market PerformN/AView Rating Details
2/11/2016Oppenheimer Holdings, Inc.Reiterated RatingOutperformN/AView Rating Details
(Data available from 8/20/2015 forward)

Earnings

Earnings History for Tokai Pharmaceuticals (NASDAQ:NVUS)
Earnings by Quarter for Tokai Pharmaceuticals (NASDAQ:NVUS)
Earnings History by Quarter for Tokai Pharmaceuticals (NASDAQ NVUS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/10/2016Q1($0.50)($0.51)ViewN/AView Earnings Details
3/10/2016Q4($0.47)($0.49)ViewN/AView Earnings Details
11/10/2015Q3($0.53)($0.53)$6.03 millionViewN/AView Earnings Details
8/12/2015Q215($0.50)($0.40)ViewN/AView Earnings Details
5/12/2015Q115($0.31)($0.59)ViewN/AView Earnings Details
3/12/2015($0.40)($0.28)ViewN/AView Earnings Details
11/10/2014($0.42)($2.71)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Tokai Pharmaceuticals (NASDAQ:NVUS)
Current Year EPS Consensus Estimate: $-9.99 EPS
Next Year EPS Consensus Estimate: $-0.39 EPS

Dividends

Dividend History for Tokai Pharmaceuticals (NASDAQ:NVUS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Tokai Pharmaceuticals (NASDAQ:NVUS)
Insider Ownership Percentage: 39.90%
Institutional Ownership Percentage: 34.75%
Insider Trades by Quarter for Tokai Pharmaceuticals (NASDAQ:NVUS)
Insider Trades by Quarter for Tokai Pharmaceuticals (NASDAQ:NVUS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/10/2017Catherine C. TurkelInsiderBuy11,111$9.99$110,998.89View SEC Filing  
5/10/2017Gregory J. FlesherCEOBuy58,959$9.99$589,000.41View SEC Filing  
3/15/2016Stephen Jr. BuckleyDirectorBuy8,000$5.74$45,920.00View SEC Filing  
11/11/2015Stephen Jr. BuckleyDirectorBuy3,000$11.25$33,750.00View SEC Filing  
9/21/2015John S. McbrideCOOSell13,500$14.01$189,135.00View SEC Filing  
9/8/2015Lee KalowskiCFOSell4,668$13.13$61,290.84View SEC Filing  
9/2/2015Lee KalowskiCFOSell2,158$12.96$27,967.68View SEC Filing  
7/15/2015Bioventures Ltd NovartisMajor ShareholderSell3,566$14.26$50,851.16View SEC Filing  
7/14/2015Bioventures Ltd NovartisMajor ShareholderSell27,861$14.41$401,477.01View SEC Filing  
7/13/2015Bioventures Ltd NovartisMajor ShareholderSell20,611$14.20$292,676.20View SEC Filing  
6/29/2015Jodie Pope MorrisonCEOSell16,000$13.77$220,320.00View SEC Filing  
6/24/2015John S McbrideCOOSell9,000$14.01$126,090.00View SEC Filing  
6/23/2015John S McbrideCOOSell6,700$14.00$93,800.00View SEC Filing  
6/22/2015John S McbrideCOOSell2,000$14.02$28,040.00View SEC Filing  
6/16/2015Bioventures Ltd NovartisMajor ShareholderSell1,120$14.27$15,982.40View SEC Filing  
6/11/2015Bioventures Ltd NovartisMajor ShareholderSell27,875$14.20$395,825.00View SEC Filing  
4/16/2015Lee KalowskiCFOSell4,567$13.00$59,371.00View SEC Filing  
4/2/2015Lee KalowskiCFOSell2,258$11.45$25,854.10View SEC Filing  
3/19/2015Bioventures Ltd NovartisMajor ShareholderSell49,141$14.50$712,544.50View SEC Filing  
9/22/2014Apple Tree Partners Ii - AnnexDirectorBuy237,500$15.00$3,562,500.00View SEC Filing  
9/22/2014Bioventures Ltd NovartisMajor ShareholderBuy325,000$15.00$4,875,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Tokai Pharmaceuticals (NASDAQ:NVUS)
Latest Headlines for Tokai Pharmaceuticals (NASDAQ:NVUS)
Source:
DateHeadline
americanbankingnews.com logoCritical Contrast: Tokai Pharmaceuticals (NVUS) and ChemoCentryx (CCXI)
www.americanbankingnews.com - August 18 at 12:22 AM
finance.yahoo.com logoNovus Therapeutics Reports Second Quarter 2017 Results
finance.yahoo.com - August 10 at 6:20 AM
americanbankingnews.com logo-$2.70 Earnings Per Share Expected for Tokai Pharmaceuticals, Inc. (NVUS) This Quarter
www.americanbankingnews.com - August 4 at 2:18 PM
americanbankingnews.com logoOcera Therapeutics (OCRX) vs. Tokai Pharmaceuticals (NASDAQ:NVUS) Critical Analysis
www.americanbankingnews.com - July 29 at 12:35 PM
americanbankingnews.com logo Analysts Anticipate Tokai Pharmaceuticals, Inc. (NASDAQ:NVUS) to Post -$2.70 Earnings Per Share
www.americanbankingnews.com - July 13 at 8:29 AM
americanbankingnews.com logoTokai Pharmaceuticals, Inc. (NASDAQ:NVUS) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - July 12 at 10:21 AM
americanbankingnews.com logoTokai Pharmaceuticals, Inc. (NVUS) Expected to Announce Earnings of -$2.70 Per Share
www.americanbankingnews.com - June 19 at 8:16 AM
americanbankingnews.com logoComparing Syndax Pharmaceuticals (SNDX) and Tokai Pharmaceuticals (NVUS)
www.americanbankingnews.com - June 16 at 6:08 PM
americanbankingnews.com logoComparing Alexion Pharmaceuticals (ALXN) & Tokai Pharmaceuticals (NVUS)
www.americanbankingnews.com - June 16 at 8:48 AM
finance.yahoo.com logoNovus Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
finance.yahoo.com - June 12 at 8:47 AM
americanbankingnews.com logoFinancial Contrast: Mirna Therapeutics (MIRN) versus Novus Therapeutics (NVUS)
www.americanbankingnews.com - June 10 at 2:46 PM
americanbankingnews.com logoNovus Therapeutics Inc (NVUS) Insider Catherine C. Turkel Buys 11,111 Shares
www.americanbankingnews.com - May 12 at 7:42 AM
americanbankingnews.com logoInsider Buying: Novus Therapeutics Inc (NVUS) CEO Buys 58,959 Shares of Stock
www.americanbankingnews.com - May 12 at 7:40 AM

Social

Chart

Tokai Pharmaceuticals (NVUS) Chart for Sunday, August, 20, 2017

This page was last updated on 8/20/2017 by MarketBeat.com Staff